You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR013/#1503  Toripalimab combined with bevacizumab and chemotherapy as first-line treatment for refractory, recurrent or metastatic cervical cancer: a single-arm, open-label, phase II TRIA

Citation Tools

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS03. Cervical cancer
PR013/#1503  Toripalimab combined with bevacizumab and chemotherapy as first-line treatment for refractory, recurrent or metastatic cervical cancer: a single-arm, open-label, phase II TRIA
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Li C, Peng P, Yao H, et al
PR013/#1503  Toripalimab combined with bevacizumab and chemotherapy as first-line treatment for refractory, recurrent or metastatic cervical cancer: a single-arm, open-label, phase II TRIA
International Journal of Gynecologic Cancer 2023;33:A37.